FDA Evaluates Rare Lymphoma Link To Breast Implants

FDA Evaluates Rare Lymphoma Link To Breast Implants

Since 2011, the FDA has been studying the link between anaplastic large cell lymphoma (ALCL), a rare type of non-Hodgkin’s lymphoma, and breast implants.

Since February 1, 2017, the FDA received 359 reports of cancer associated with the implants and women are now considering whether they should file breast implant lawsuits.

textured breast implant mentor implants recall
Table of Contents

FDA Warns of ALCL in Women with Breast Implants

In 2011, the FDA first identified a possible association between breast implants and the development of a rare form of cancer.

In the more recent FDA statement, the FDA acknowledged that they have “strengthened our understanding of this condition and concur with the World Health Organization designation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a rare T-cell lymphoma that can develop following breast implants.”

According to the FDA, the data suggests that BIA-ALCL occurs most frequently after implantation of breast implants with textured surfaces rather than those with smooth surfaces.

As of February 1, 2017, the agency has received 359 medical device reports of BIA-ALCL, including nine deaths.

Of the 231 reports that included information on the implant surface, 203 involved textured implants and 28 smooth implants.

186 concerned implants filled with silicone gel while 126 described those filled with saline.

What is BIA-ALCL?

BIA-ALCL is an extremely rare lymphoma (one on 300,000 breast implants), not cancer of the breast tissue.

When breast implants are placed within the body, they are inserted behind the breast tissue or under the chest muscle.

Over time, a fibrous scar (known as a capsule) forms around the implant, separating it from the rest of the breast.

In women with breast implants, the ALCL was generally found adjacent to the implant itself, contained within the fibrous capsule.

The most common symptom of BIA-ALCL is a swollen breast presenting a year or more after implant placement.

Treatment for the condition typically involves capsulectomy and implant removal.

Patients with a more aggressive mass may require cytotoxic chemotherapy in addition to removal of the implants.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources